CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]

Mehta, Priyanka, Murphy, Roderick, Park, Saemi, Faderl, Stefan, Skacel, Tomas, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Johnson, Sean and Legg, Alex 2026. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial [Letter]. Leukemia & Lymphoma 67 (10) , pp. 2159-2163. 10.1080/10428194.2026.2690155

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Item Type:	Short Communication
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine Research Institutes & Centres > Centre for Trials Research (CNTRR)
Publisher:	Taylor and Francis Group
ISSN:	1042-8194
Date of First Compliant Deposit:	2 September 2026
Last Modified:	02 Sep 2026 11:15
URI:	https://orca.cardiff.ac.uk/id/eprint/188123

Actions (repository staff only)

Edit Item